Filing Flows

Filing Flows › 8-K events › Milestone Pharmaceuticals

Milestone Pharmaceuticals: notice of delisting or failure to meet a listing standard

Form 8-K filed Oct 28, 2026 · items 3.01

What the filing says

On October 23, 2026, Milestone Pharmaceuticals Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common shares was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Na

Read the filing on SEC EDGAR →

What usually followsAcross 492 8-Ks reporting Item 3.01 (delisting notice or listing-rule failure) in our universe, the stock's median move the next session was 0.0% (typical size ±2.1%, up 46% of the time); over the following 21 sessions, −0.2%. Every item ranked →

What this kind of filing means

Item 3.01 — Notice of delisting or failure to meet a listing standard. A delisting notice starts a compliance window; companies often answer with a reverse split, a plan, or a move to another market.

Milestone Pharmaceuticals at a glance

Latest quarterQ2 2026
Revenue$559K
Operating marginn/m
IndustryPharmaceutical Preparations

Milestone Pharmaceuticals, Q2 2026: revenue $559K. The chart follows the revenue to costs, profit and cash.

Milestone Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent delisting notices

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.